Interestingly, CD96 is upregulated in AML LSCs with increased relapse rate and poor chemotherapy responses, indicating that an anti-CD96 antibody could be used for targeted immunotherapy [157]. The gene discussed is CD96; the disease is acute myeloid leukemia.